Literature DB >> 15225170

Clinical and histological features of non-alcoholic fatty liver disease in Hong Kong Chinese.

V W-S Wong1, H L-Y Chan, A Y Hui, K-F Chan, C-T Liew, F K-L Chan, J J-Y Sung.   

Abstract

BACKGROUND: Non-alcoholic fatty liver disease is prevalent in affluent countries and is a cause of cirrhosis and possibly hepatocellular carcinoma. AIM: To examine the clinical and histological features of biopsy-proven non-alcoholic fatty liver disease and investigate the predictors of severe histological disease in Chinese patients.
METHODS: Electronic records of all patients (n = 247) who underwent liver biopsy between 1996 and 2003 in our hospital were retrieved. Patients who had histological features of non-alcoholic fatty liver disease were identified. The demographic, clinical, laboratory and histological (Brunt's criteria) parameters of these patients were analysed.
RESULTS: Forty-two patients had histology-proven non-alcoholic fatty liver disease. The median age was 47 years (range 23-69). All except one patient had features of metabolic syndrome. The median alanine aminotransferase was 93 (range 24-270) IU/L. Thirty-six (85.7%) patients had steatohepatitis and 11 (26.1%) also had fibrosis. Only one patient had stage 3 fibrosis. The presence of diabetes mellitus predicted higher grade steatohepatitis and fibrosis (P = 0.019) whereas alanine aminotransferase level had no correlation with histological severity of steatohepatitis. After a median follow-up of 42 months, no patient developed hepatic decompensation.
CONCLUSIONS: Most Chinese patients with non-alcoholic fatty liver disease had features of the metabolic syndrome. Histological activity was generally mild. Diabetes mellitus was the most important predictor of severe histological disease.

Entities:  

Mesh:

Year:  2004        PMID: 15225170     DOI: 10.1111/j.1365-2036.2004.02012.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  11 in total

1.  Transient elastography in chronic hepatitis B: an Asian perspective.

Authors:  Seung Up Kim; Kwang-Hyub Han; Sang Hoon Ahn
Journal:  World J Gastroenterol       Date:  2010-11-07       Impact factor: 5.742

2.  Association Between Elevated Liver Enzymes and Metabolic Syndrome Among Thai Adults.

Authors:  Sajithya Perera; Vitool Lohsoonthorn; Wiroj Jiamjarasrangsi; Somrat Lertmaharit; Michelle A Williams
Journal:  Diabetes Metab Syndr       Date:  2008-09

Review 3.  Prognostic implication of liver histology in patients with nonalcoholic fatty liver disease in diabetes.

Authors:  Iliana Doycheva; Niraj Patel; Michael Peterson; Rohit Loomba
Journal:  J Diabetes Complications       Date:  2013-01-09       Impact factor: 2.852

4.  Efficacy of Tumor Necrosis Factor and Interleukin-10 Analysis in the Follow-up of Nonalcoholic Fatty Liver Disease Progression.

Authors:  Walid E Zahran; Kholoud A Salah El-Dien; Philip G Kamel; Ahmed Shawky El-Sawaby
Journal:  Indian J Clin Biochem       Date:  2012-07-14

Review 5.  Systematic review on the treatment of pentoxifylline in patients with non-alcoholic fatty liver disease.

Authors:  Wenjun Li; Liu Zheng; Chunjun Sheng; Xiaoyun Cheng; Liu Qing; Shen Qu
Journal:  Lipids Health Dis       Date:  2011-04-08       Impact factor: 3.876

6.  Non-alcoholic fatty liver disease and correlation of serum alanin aminotransferase level with histopathologic findings.

Authors:  Somaye Khosravi; Seyed Moayed Alavian; Ali Zare; Nasser Ebrahimi Daryani; Seyed-Mohammad Fereshtehnejad; Narges Ebrahimi Daryani; Mohammad Reza Keramati; Sina Abdollahzade; Sahar Taba Taba Vakili
Journal:  Hepat Mon       Date:  2011-06       Impact factor: 0.660

7.  Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD.

Authors:  Jessica Bazick; Michele Donithan; Brent A Neuschwander-Tetri; David Kleiner; Elizabeth M Brunt; Laura Wilson; Ed Doo; Joel Lavine; James Tonascia; Rohit Loomba
Journal:  Diabetes Care       Date:  2015-04-17       Impact factor: 19.112

8.  A CONSORT-compliant, randomized, double-blind, placebo-controlled pilot trial of purified anthocyanin in patients with nonalcoholic fatty liver disease.

Authors:  Pei-Wen Zhang; Feng-Xia Chen; Di Li; Wen-Hua Ling; Hong-Hui Guo
Journal:  Medicine (Baltimore)       Date:  2015-05       Impact factor: 1.889

9.  Effects of metabolic syndrome on fibrosis in chronic viral hepatitis.

Authors:  Harry Yoon; Jeong Guil Lee; Jeong Hwan Yoo; Myung Su Son; Dae Young Kim; Seong Gyu Hwang; Kyu Sung Rim
Journal:  Gut Liver       Date:  2013-06-20       Impact factor: 4.519

10.  Serum amylase levels are decreased in Chinese non-alcoholic fatty liver disease patients.

Authors:  Jinmei Yao; Ying Zhao; Juanwen Zhang; Yani Hong; Huanle Lu; Jianping Wu
Journal:  Lipids Health Dis       Date:  2014-12-07       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.